A Phase Ib/II Study of AZD0120, Dual-Targeting CAR-T Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma - DURGA-1

Inclusion Criteria

• Inclusion Criteria:
• • ≥18 years of age at the time of consent.
• • ECOG performance status of 0 or 1.
• • Documented diagnosis of MM per IMWG diagnostic criteria.
• • Participant must have received at least 3 prior lines of therapy, which include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody.
• • Have documented evidence of progressive disease per IMWG criteria.
• • Subjects must have measurable disease at screening.
• • Adequate bone marrow function and other organ functions (hematological, hepatic and renal) must be demonstrated at screening.
• Exclusion Criteria :
• • Participant has a history of significant toxicity during prior CAR T-cell therapy and T-cell engaging therapy.
• • Participant has a history of a prior non-hematologic malignancy, unless the participant has been disease-free with no evidence of recurrence for ≥ 2 years. Some exceptions may apply.
• • Participant has significant cardiac neurological, or psychiatric conditions.
• • Any other significant medical conditions such as:
• o Serious active or uncontrolled infection
• o Active autoimmune disease or a history of autoimmune disease within 2 years
• o Active plasma cell leukemia at the time of screening
• o Clinical evidence of dementia or altered mental status, or stroke, intracranial haemorrhage, or seizure within 6 months before signing informed consent form (ICF).
• • Known active or prior history of central nervous system involvement or exhibits clinical signs of meningeal involvement of MM.
• Other protocol-defined Inclusion/Exclusion criteria apply.